Evidence map›Paper›PMID 37037958›Full record

ArticleInternational journal of hematology2023

Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia.

Chihaya Imai, Atsushi Sato, Mitsuteru Hiwatari, Yasuto Shimomura, Toshinori Hori, Souichi Suenobu, Toshihiko Imamura, Junichi Hara, Daisuke Hasegawa, Hiroyuki Takahashi and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 1 country.

Chihaya ImaiDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuou-Ku, Niigata City, Niigata, 951-8510, Japan. chihaya@med.niigata-u.ac.jp.ORCID http://orcid.org/0000-0001-7435-3464
Atsushi SatoDepartment of Hematology and Oncology, Miyagi Children's Hospital, Miyagi, Japan.
Mitsuteru HiwatariDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yasuto ShimomuraDepartment of Pediatrics, Aichi Medical University, Aichi, Japan.
Toshinori HoriDepartment of Pediatrics, Aichi Medical University, Aichi, Japan.
Souichi SuenobuDepartment of Pediatrics, Oita University, Oita, Japan.
Toshihiko ImamuraDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Junichi HaraDepartment of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan.
Daisuke HasegawaDepartment of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
Hiroyuki TakahashiDepartment of Pediatrics, Toho University Omori Medical Center, Tokyo, Japan.
Kunihiko MoriyaDepartment of Pediatrics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Saori KatayamaDepartment of Pediatrics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Daisuke TomizawaChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Hiroshi MoritakeDepartment of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Takashi TagaDepartment of Pediatrics, Shiga University of Medical Science, Shiga, Japan.
Keizo HoribeClinical Research Center, Nagoya Medical Center, Nagoya, Japan.
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Atsushi ManabeDepartment of Pediatrics, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Yasuhiro OkamotoDepartment of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Aichi Medical University · JPTohoku University · JPHokkaido University · JPKagoshima University · JPKyoto Prefectural University of Medicine · JPMiyagi Children's Hospital · JPNagoya Medical Center · JPNational Center For Child Health and Development · JPNiigata University Medical and Dental Hospital · JPOita University · JPOsaka City General Hospital · JPSaitama Children's Medical Center · JPShiga University of Medical Science · JPSt. Luke's International Hospital · JPThe University of Tokyo · JPToho University · JPUniversity of Miyazaki · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The characteristics and prognosis of Japanese children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission after remission induction chemotherapy (i.e., experience induction failure) are poorly understood. Therefore, we retrospectively analyzed data of patients enrolled in Japanese clinical trials for newly diagnosed ALL between 1996 and 2009. Among 4956 participants, 89 (1.8%) experienced induction failure. With a 6.0-year median follow-up, the 5-year overall survival rate of the entire cohort was 43.0% ± 5.5%. Survival rates did not differ between patients with B-cell precursor ALL (BCP-ALL) and T-cell ALL (T-ALL). In multivariate analysis, day 15 M3 marrow (bone marrow blast count ≥ 25%) was significantly correlated with poorer survival in the whole or BCP-ALL cohorts. In T-ALL, age < 6 years was significantly associated with poor survival. However, due to the small sample size, this correlation must be further investigated. Most T-ALL and BCR-ABL-positive BCP-ALL patients underwent allogeneic stem cell transplantation (allo-SCT). Survival rates did not differ between BCR-ABL-negative BCP-ALL patients who did and did not undergo allo-SCT, possibly due to the inclusion of lower-risk patients in the latter group. In conclusion, the induction failure rate and survival after diagnosis of induction failure in our study were comparable to previously reported figures.

Indexed as

Hematopoietic Stem Cell TransplantationPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaChildEast Asian PeopleFusion Proteins, bcr-ablHumansPrognosisRemission InductionRetrospective StudiesTreatment OutcomeFusion Proteins, bcr-ablAcute lymphoblastic leukemiaInduction failureResistant disease

Identifiers

PMID37037958
OpenAlexW4362737298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.